Emerging pharmaceuticals that target metabolic and endocrine dysfunctions in polycystic ovary syndrome are transforming treatment paradigms. This article covers innovative drugs, including glucagon-like peptide 1 receptor agonists, sodium–glucose cotransporter 2 inhibitors, kisspeptin, neurokinin 3 receptor antagonists and artemisinins, exploring their mechanisms and potential to advance care for this disorder.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Elkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J. & Bellanger, D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil. Steril. 118, 371–381 (2022).
Sanchez-Garrido, M. A. et al. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy. Nat. Commun. 15, 8498 (2024).
Lempesis, I. G. et al. Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome. Diabetes Metab. Res. Rev. 39, e3682 (2023).
Rakic, D. et al. Multiple benefits of empagliflozin in PCOS: evidence from a preclinical rat model. Pathophysiology 31, 559–582 (2024).
Lin, B. et al. Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome. Eur. J. Pharmacol. 977, 176742 (2024).
Coutinho, E. A. et al. Targeted inhibition of kisspeptin neurons reverses hyperandrogenemia and abnormal hyperactive LH secretion in a preclinical mouse model of polycystic ovary syndrome. Hum. Reprod. 39, 2089–2103 (2024).
Romero-Ruiz, A. et al. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome. Hum. Reprod. 34, 2495–2512 (2019).
Fraser, G. L. et al. Randomized controlled trial of neurokinin 3 receptor antagonist fezolinetant for treatment of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 106, e3519–e3532 (2021).
Skorupskaite, K., George, J. T., Veldhuis, J. D., Millar, R. P. & Anderson, R. A. Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome. Hum. Reprod. 35, 1421–1431 (2020).
Liu, Y. et al. Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction. Science 384, eadk5382 (2024).
Acknowledgements
The authors are supported by the National Natural Science Foundation of China (82471670) and the National Science and Technology Council (NSTC 113-2314-B-039-055).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Zhou, K., Lou, C., Chang, PH. et al. Promising drugs for PCOS: targeting metabolic and endocrine dysfunctions. Nat Rev Endocrinol 21, 455–456 (2025). https://doi.org/10.1038/s41574-025-01121-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41574-025-01121-z
